08:00 , Nov 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-17A (IL-17A); calcium channel

Endocrine/metabolic disease INDICATION: Thyroid disease Patient sample and mouse studies suggest IL-17A inhibitors or calcium channel blockers could help treat bone loss in primary hyperparathyroidism (PHPT). In peripheral blood nucleated cells from patients, levels of IL-17A mRNA...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

Dolizem diltiazem cream: Development discontinued

Assembly said it will not pursue further development of VEN 307 and ended a March 2007 deal with S.L.A. Pharma granting Assembly exclusive, North American rights to the product for the topical treatment of anal...
07:00 , Apr 7, 2014 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Small but mighty

Despite a correction at the end of March, all biotech market cap segments finished the first quarter in positive territory. Microcaps set the pace with a 10% gain, while large caps added 7% and were...
08:00 , Feb 17, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Cubist Pharmaceuticals Inc. (NASDAQ:CBST) was up $0.73 to $73.55 last week after FDA's Anti-Infective Drugs Advisory Committee said it will meet on March 31 to discuss a pair of NDAs covering IV and oral...
08:00 , Feb 17, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/14 cls Depomed Inc. (NASDAQ:DEPO) Roth Capital Partners Scott Henry Downgrade Neutral (from...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Diltiazem cream: Phase III data

Top-line data from a double-blind, international Phase III trial in 434 patients with anal fissures showed that thrice-daily 2% diltiazem cream missed the primary endpoint of reducing the average of worst anal pain associated with...
02:33 , Feb 13, 2014 |  BC Extra  |  Clinical News

Ventrus cream misses in Phase III anal fissure trial

Ventrus Biosciences Inc. (NASDAQ:VTUS) said thrice-daily 2% diltiazem cream ( VEN 307) missed the primary endpoint of reducing the average of worst anal pain associated with or following defecation from baseline to week four vs....
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for growth....
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Diltiazem cream: Completed Phase III enrollment

Ventrus completed enrollment of 434 patients with anal fissures in a double-blind, placebo-controlled, international Phase III trial evaluating thrice-daily 2% diltiazem cream for 28 days. In May 2012, the company reported data from its first...
07:00 , May 13, 2013 |  BioCentury  |  Product Development

An association for dissociation

Forest Laboratories Inc.'s investment and option deal with Trevena Inc. last week will support the translation of a successful mechanism for treating chronic heart failure into the acute setting, as well as the development of...